EQL Pharma AB (publ) (STO:EQL)
Sweden · Delayed Price · Currency is SEK 26.30
+1.15 (4.57%)
At close: Aug 14, 2026
EQL Pharma AB Income Statement
Financials in millions SEK. Fiscal year is April - March.
Millions SEK. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 432.35 | 432.66 | 373.52 | 264.17 | 259.91 | 409.75 |
| 432.35 | 432.66 | 373.52 | 264.17 | 259.91 | 409.75 | |
Revenue Growth | 8.65% | 15.83% | 41.39% | 1.64% | -36.57% | 128.73% |
Cost of Revenue | 297.83 | 269.82 | 217.56 | 149.12 | 144.06 | 314.02 |
Gross Profit | 134.53 | 162.84 | 155.95 | 115.05 | 115.85 | 95.73 |
Selling, General & Admin | 106.78 | 102.92 | 78.46 | 70.8 | 59.79 | 48.16 |
Research & Development | 15.77 | 14.33 | 11.26 | 12.09 | 15.14 | 9.13 |
Other Operating Expenses | -1.72 | -2.19 | -0.52 | -0.46 | -0.41 | -0.4 |
Operating Expenses | 120.83 | 115.06 | 89.2 | 82.43 | 74.51 | 56.9 |
Operating Income | 13.7 | 47.78 | 66.75 | 32.62 | 41.34 | 38.84 |
Interest Expense | -25.79 | -26.39 | -12.34 | -5.73 | -2.37 | -2.87 |
Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0.2 | 0 | - |
Other Non Operating Income (Expenses) | -4.1 | -4.1 | -0.68 | -0 | - | 0 |
EBT Excluding Unusual Items | -16.18 | 17.3 | 53.74 | 27.08 | 38.97 | 35.97 |
Gain (Loss) on Sale of Investments | - | - | - | 1.53 | - | - |
Pretax Income | -15.28 | 18.21 | 54.36 | 28.6 | 38.97 | 35.97 |
Income Tax Expense | -1.24 | 5.67 | 11.23 | 5.9 | 8.05 | 4.42 |
Net Income | -14.04 | 12.54 | 43.12 | 22.71 | 30.92 | 31.55 |
Net Income to Common | -14.04 | 12.54 | 43.12 | 22.71 | 30.92 | 31.55 |
Net Income Growth | - | -70.93% | 89.93% | -26.57% | -1.99% | 204.32% |
Shares Outstanding (Basic) | 30 | 30 | 29 | 29 | 29 | 29 |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 30 | 29 |
Shares Change | -1.52% | 0.92% | 0.34% | 0.91% | 1.59% | - |
EPS (Basic) | -0.47 | 0.42 | 1.48 | 0.78 | 1.06 | 1.09 |
EPS (Diluted) | -0.47 | 0.42 | 1.44 | 0.76 | 1.04 | 1.09 |
EPS Growth | - | -70.83% | 89.47% | -26.92% | -4.19% | 204.32% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 21.22 | 22.92 | -30.78 | -12.36 | 27.16 | 41.2 |
Free Cash Flow Per Share | 0.72 | 0.76 | -1.03 | -0.41 | 0.92 | 1.42 |
Gross Margin | 31.11% | 37.64% | 41.75% | 43.55% | 44.57% | 23.36% |
Operating Margin | 3.17% | 11.04% | 17.87% | 12.35% | 15.90% | 9.48% |
Profit Margin | -3.25% | 2.90% | 11.54% | 8.60% | 11.90% | 7.70% |
Free Cash Flow Margin | 4.91% | 5.30% | -8.24% | -4.68% | 10.45% | 10.05% |
EBITDA | 34.31 | 65.93 | 75.06 | 38.81 | 47.37 | 40.54 |
EBITDA Margin | 7.94% | 15.24% | 20.09% | 14.69% | 18.23% | 9.89% |
D&A For EBITDA | 20.61 | 18.15 | 8.31 | 6.19 | 6.03 | 1.7 |
EBIT | 13.7 | 47.78 | 66.75 | 32.62 | 41.34 | 38.84 |
EBIT Margin | 3.17% | 11.04% | 17.87% | 12.35% | 15.90% | 9.48% |
Effective Tax Rate | - | 31.13% | 20.66% | 20.62% | 20.65% | 12.28% |